Skip to main content

Table 2 Comparison of clinicopathological characteristics before and after PSM in neoadjuvant group

From: Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study

Patient Characteristics

Unmatched comparison

Matched comparison

Patients with NEC components (n = 63)

Gastric adenocarcinoma (n = 477)

P value

Patients with NEC components (n = 60)

Gastric adenocarcinoma (n = 120)

P value

Age (year), mean ± SD

61.2 ± 9.6

58.3 ± 10.3

0.037

61.3 ± 9.7

60.2 ± 9.5

0.484

Gender (male/female)

52/11

367/110

0.316

50/10

104/16

0.549

BMI, mean ± SD

24.1 ± 3.9

23.5 ± 3.4

0.285

23.9 ± 3.9

23.8 ± 3.4

0.855

Adjuvant therapy

  

0.124

  

0.173

 Yes

58 (92.1)

459 (96.2)

 

56 (93.9)

117 (97.5)

 

 No

5 (7.9)

18 (3.8)

 

4 (6.7)

3 (2.5)

 

Tumor location

  

< 0.001

  

0.361

 Upper third

46 (73.0)

222 (46.5)

 

43 (71.7)

79 (65.8)

 

 Middle third

9 (14.3)

50 (10.5)

 

9 (15.0)

13 (10.8)

 

 Lower third

7 (11.1)

189 (39.6)

 

7 (11.7)

21 (17.5)

 

 Entire

1 (1.6)

16 (3.4)

 

1 (1.7)

7 (5.8)

 

Tumor size

  

0.325

  

0.594

 < 5 cm

36 (57.1)

303 (63.5)

 

33 (55.0)

71 (59.2)

 

 ≥ 5 cm

27 (42.9)

174 (36.5)

 

27 (45.0)

49 (40.8)

 

Type of gastrectomy

  

< 0.001

  

0.974

 Total gastrectomy

50 (79.4)

239 (50.1)

 

47 (78.3)

94 (78.3)

 

 Distal gastrectomy

7 (11.1)

181 (37.9)

 

7 (11.7)

15 (12.5)

 

 Proximal gastrectomy

6 (9.5)

57 (11.9)

 

6 (10.0)

11 (9.2)

 

Surgical procedure

  

0.394

  

1.000

 Open

60 (95.2)

440 (92.2)

 

57 (95.0)

114 (95.0)

 

 Laparoscopic

3 (4.8)

37 (7.8)

 

3 (5.0)

6 (5.0)

 

T stage

  

< 0.001

  

0.065

 T0

1 (1.6)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

 T1

3 (4.8)

28 (5.9)

 

3 (5.0)

3 (2.5)

 

 T2

3 (4.8)

60 (12.6)

 

3 (5.0)

15 (12.5)

 

 T3

35 (55.6)

154 (32.3)

 

34 (56.7)

47 (39.2)

 

 T4

21 (33.3)

235 (49.6)

 

20 (33.3)

55 (45.8)

 

N stage

  

0.017

  

0.186

 N0

17 (27.0)

158 (33.1)

 

16 (26.7)

44 (36.7)

 

 N1

22 (34.9)

99 (20.8)

 

21 (35.0)

33 (27.5)

 

 N2

14 (22.2)

80 (16.8)

 

14 (23.3)

17 (14.2)

 

 N3

10 (15.9)

140 (29.4)

 

9 (15.0)

26 (21.7)

 

M stage

  

0.041

  

0.721

 M0

60 (95.2)

471 (98.7)

 

59 (98.3)

117 (97.5)

 

 M1

3 (4.8)

6 (1.3)

 

1 (1.7)

3 (2.5)

 

ypTNM stage

  

0.001

  

0.950

 0

1 (1.6)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

 I

4 (6.3)

52 (10.9)

 

4 (6.7)

6 (5.0)

 

 II

31 (49.2)

163 (34.2)

 

31 (51.7)

64 (53.3)

 

 III

24 (38.1)

256 (53.7)

 

24 (40.0)

47 (39.2)

 

 IV

3 (4.8)

6 (1.3)

 

1 (1.7)

3 (2.5)

 
  1. BMI Body Mass Index, MiNEN Mixed neuroendocrine-non-neuroendocrine neoplasm, NEC neuroendocrine carcinoma, PSM Propensity Score Matching
  2. Patients with NEC components: NEC, < 30% high grade MiNEN, high grade MiNEN and > 70% high grade MiNEN